ArticleFrontiers in human neuroscience2026
Case Report: Anodal DLPFC-tDCS for refractory post-traumatic cognitive fatigue in the hypometabolic brain.
Article in Frontiers in human neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cognitive fatigue is among the most common and disabling long-term sequelae of mild traumatic brain injury (mTBI), with limited effective treatment options. We report a case of refractory post-mTBI cognitive fatigue treated with home-based anodal transcranial direct current stimulation (tDCS) guided by FDG-PET/MRI findings. Case presentation: A patient sustained an mTBI in 2013 following a high-speed motorcycle accident, with possible loss of consciousness and approximately four hours of post-traumatic amnesia. Despite more than a decade of multidisciplinary rehabilitation, he remained unable to return to work due to severe cognitive fatigue (Fatigue Severity Scale [FSS-7] 5.4/7), post-traumatic headache, fatigue-exacerbated dysarthria, photophobia, phonophobia, and poor sleep (STOP-Bang score: 5, high risk for OSA). At the time of treatment, he was taking methylphenidate and galcanezumab. Pre-treatment FDG-PET/MRI demonstrated bilateral prefrontal hypometabolism (left greater than right) and parietal hypometabolism, with relative hypermetabolism in the left temporal lobe, anterior cingulate cortex, and brainstem. These findings informed selection of the left dorsolateral prefrontal cortex (DLPFC) as the stimulation target. Intervention: A 14-day home-based tDCS protocol was administered, with the first session completed in clinic. Stimulation was delivered at 2 mA for 20 min daily using an anode placed over F3 (left DLPFC) and cathode over F4 (right DLPFC), concurrent with structured cognitive exercises. Outcomes: Following treatment, fatigue improved substantially (FSS-7: 5.4 to 3.7), exceeding the reported minimal clinically important difference. Modified Fatigue Impact Score (MFIS: 31 to 27), including the cognitive fatigue subscale (21 to 16). Cognitive performance also improved, with gains in processing speed (Symbol Digit Modalities Test: 46 to 58) and global cognition (Montreal Cognitive Assessment: 26 to 29). Measures of mood, anxiety, and quality of life remained stable. No serious adverse events were reported. Conclusion: Home-based anodal tDCS targeting the left DLPFC was associated with clinically meaningful reductions in chronic post-mTBI cognitive fatigue and improvements in cognitive performance. This case highlights the potential utility of FDG-PET/MRI as a biomarker to guide personalized neuromodulation and supports further investigation of DLPFC-targeted tDCS for treatment-resistant post-traumatic fatigue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.